Bial and Neuricrine sign partnership
Bial e Neuricrine firmam parceria
Intel ID : 245161
| Synopsis |
|
Bial, a Portugal-based pharmaceutical company, and the US-based Neuricrine signed a partnership, reported Expresso on 10 February 2017, citing a statement published by Bial. The partnership focuses on the development of a medicine for Parkinson in North America. The initial payment will be EUR 28m and can reach USD 145m.
(content in portuguese)
A Bial, farmacêutica portuguesa, e a norte-americana Neuricrine firmam uma parceria, segundo publicou o Expresso no dia 10 de fevereiro de 2017, citando um comunicado da Bial. A parceria centra-se no desenvolvimento e comercialização na América do Norte, de um medicamento para a doença de Parkinson. O pagamento inicial será de EUR 28m, e pode atiingir os USD 145m. |
|
||||
| Intel ID | 245161 | |
| Value | ND | |
| Native Currency | Euro (EUR) | |
|
Financial Data - Bial
(31 Dec 2023) |
Revenue: - EBITDA: - Net Debt: - People: 388 |
|
| Date |
 |
|
| Country | |
|
| Region | ||
| Continent |  |
|
| Geography | |
|
| Subsector (Old TTR Sectors) |
|
|
| Type |
|
|
| Intel Grade |
|
|
| Source |
|
|
| Tags | |
Target
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Target
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Country |
|
||
| Website |
|
||
| Description |
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.